Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
Condition studied
Homozygous Familial Hypercholesterolemia (HoFH)
Investigational medicinal product(s)
Every trial of Zodasiran across our registers →
Eligibility
Primary endpoint
Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period)
Endpoint detail
1. Change and percent change from Baseline to Month 12 in Fasting Apolipoprotein B (ApoB) (Randomized Period), 2. Change and percent change from Baseline to Month 12 in Fasting Non-High Density Lipoprotein Cholesterol (non-HDL-C) (Randomized Period), 3. Change from Baseline to Month 12 in Fasting LDL-C (Randomized Period), 4. Area Under the Plasma Concentration Versus the Time Curve (AUC) from Baseline to Month 12 for Fasting LDL-C (Randomized Period), 5. Change and percent change from Baseline to Month 12 in Fasting Triglycerides (TGs) (Randomized Period), 6. Change and percent change from Baseline to Month 12 in Fasting Angiopoietin-like Protein 3 (ANGPTL3) (Randomized Period), 7. Change and percent change from Baseline to Month 12 in Fasting Total Cholesterol (Randomized Period), 8. Change and percent change from Baseline to Month 12 in Fasting High-Density Lipoprotein Cholesterol (HDL-C) (Randomized Period), 9. Proportion of Participants who Meet European Union (EU) LDL-C Apheresis Eligibility Criteria (per German Apheresis Working Group) at Month 12 (Randomized Period), 10. Proportion of Participants who Meet United States (US) Apheresis Eligibility Criteria (per National Lipid Association) at Month 12 (Randomized Period), 11. Proportion of Participants with Fasting LDL-C <100 mg/dL (2.6 mmol/L) at Month 12 (Randomized Period), 12. Change from Baseline in Fasting LDL-C Over Time (Randomized Period), 13. Percent change from Baseline in fasting LDL-C Over Time (Randomized Period), 14. Percent change from Baseline to Month 12 in Fasting Lipoprotein(a) [Lp(a)] (Randomized Period)
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-521792-31-01 on CTIS ↗ ← All trials in the EU